Oncolytics Begins Final Tests On Viral Cancer Drug

Within two years, a few small drug companies could begin to change the way we treat cancer. Oncolytics Biotech Inc. (ONC.T) is one company in the final stages of testing viruses that could stabilize or shrink tumors with few side effects.

Calgary-based Oncolytics has started enrolling advanced head and neck cancer patients in Phase III trials using a combination of chemotherapy and Reolysin, a drug made from a mild virus.

Reolysin "has the potential to revolutionize cancer therapy," Alan Ridgeway, an analyst at Paradigm Capital, wrote in a recent report. The drug "will likely ultimately be approved to... Read Full Article

Source: Wall Street Journal